Proxima Therapeutics

About Proxima Therapeutics

Proxima Therapeutics, Inc. was a medical device company established in 1995 by Timothy Patrick, headquartered in Alpharetta, Georgia. The firm focused on developing and marketing site-specific radiation delivery systems for treating solid cancerous tumors, initially concentrating on brain and breast cancer. The company's business model revolved around providing medical practitioners with tools for more targeted radiation therapy.

Proxima's core products were the GliaSite® and MammoSite® Radiation Therapy Systems (RTS). The GliaSite RTS, which received FDA marketing clearance in April 2001, was designed to treat malignant brain tumors. This system involved inserting a balloon catheter into the cavity left after a tumor's surgical removal and filling it with a liquid radiation source called Iotrex. This method delivered radiation directly to the surrounding tissue where tumors were most likely to recur, minimizing exposure to healthy brain tissue. The MammoSite RTS, cleared by the FDA in May 2002, applied a similar site-specific approach to treat early-stage breast cancer. This technique aimed to reduce treatment time and lessen the potential for side effects compared to traditional external beam radiation.

The company successfully navigated multiple funding rounds, raising a total of approximately $48.6 million. Its first funding round occurred in 1998, followed by a Series D of $17 million in 2001 and a Series E of $14 million in 2002. Key institutional investors included Greenspring Associates, Domain Associates, and Alta Partners. The company's trajectory culminated in its acquisition by Cytyc Corporation, a leading women's health company, in February 2005. The all-cash transaction was valued at $160 million, with an additional two-year earnout based on sales growth.